Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Autor:	Budde, Elizabeth L 1, Sehn, Laurie H 2, Matasar, Matthew 3, Schuster, Stephen J 4, Assouline, Sarit 5, Giri, Pratyush 6, Kuruvilla, John 7, Canales, Miguel 8, Dietrich, Sascha 9, Fay, Keith 10, Ku, Matthew 11, Nastoupil, Loretta 12, Wei, Michael C 13, Yin, Shen 13, Doral, Michelle Y 13, Li, Chi-Chung 13, Huang, Huang 14, Negricea, Raluca 15, Penuel, Elicia 13, O'Hear, Carol 13, Bartlett, Nancy L 16
Zdroj:	In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S117-S117
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect